CD8A and melanoma: The recombinant human hsp110-gp100 chaperone vaccine was recently tested in a phase Ib dose-escalation trial (NCT01744171), which showed minimal toxicity, measurable antitumor efficacy, and capacity to activate CD8+ T cells in patients with advanced, pretreated melanoma (11).